SAGE Therapeutics' Refractory Status Epilepticus Program Demonstrates Efficacy in First-in-Man Experience; Case Study to be Highlighted at International SE Meeting
4/4/2013 11:51:43 AM
CAMBRIDGE, Mass. & SALZBURG, Austria--(BUSINESS WIRE)--SAGE Therapeutics, a neuroscience product focused company creating novel medicines to treat important central nervous system (CNS) disorders, today announced that SGE-102, the company’s proprietary positive GABAA receptor allosteric modulator for status epilepticus (SE), will be highlighted at The 4th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures, being held April 4-6, 2013 in Salzburg, Austria. Data from the company’s preclinical SGE-102 program, a case study on the first-in-man treatment of intravenous (IV) SGE-102 in refractory SE and an overview of SAGE’s planned Phase 1/2 clinical trial of SGE-102 in patients with refractory SE will all be presented at the conference. SE is an acute, life-threatening form of epilepsy or seizures in which a patient experiences continuous or rapidly repeating seizures and occurs in approximately 200,000 U.S. patients each year.
comments powered by